A Retrospective Analysis of Polymyxin B Combined with Tigecycline in the Treatment of Multi-Drug Resistance Klebsiella pneumoniae Infection: Hypertension Increases the Incidence of Acute Kidney Injury

Multidrug resistance Klebsiella pneumoniae infection is an essential factor threatening the life of patients with severe infection. Polymyxin B widely used in treating multidrug pneumoniae, but few studies on its efficacy and safety. In our study, 205 were admitted to hospital from January 2017 December 2020, treated polymyxin for antibacterial selected as subjects. These divided into two therapy groups: A monotherapy group (polymyxin B) a combined B-tigecycline). The safety groups analyzed. Also, risk factors changes cystatin C, beta 2-microglobulin microalbuminuria showed upward trend during treatment. descent degree procalcitonin, C-reaction protein white blood cell count B-tigecycline was higher than that group. had similar effective rate, while acute kidney injury incidence Blood infection, hypertension, high dose tigecycline injury. It first time report hypertension independent when treat Patients infected pneumonia should avoid accepting combination tigecycline.